Construction and expression of a human/mouse chimeric CD19 monoclonal antibody: Successful modification of a murine IgM to a chimeric IgG

Xu,Weiqun; Zhang,Lingyan; Zhang,Yi; Tang,Yongmin

doi:10.3892/etm.2014.1511

Construction and expression of a human/mouse chimeric CD19 monoclonal antibody: Successful modification of a murine IgM to a chimeric IgG

Authors:
- Weiqun Xu
- Lingyan Zhang
- Yi Zhang
- Yongmin Tang
View Affiliations

Affiliations: Department of Hematology and Oncology, School of Medicine, Children's Hospital of Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China, Key Laboratory, The First Hospital of Ningbo City, Ningbo, Zhejiang 315700, P.R. China
Published online on: January 29, 2014 https://doi.org/10.3892/etm.2014.1511
Pages: 849-854

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

CD19 is a specific surface marker of B cells. A murine IgM‑subtype antibody, 2E8, was generated previously and assigned to the CD19 category by the 6th International Workshop and Conference on Human Leukocyte Differentiation Antigens in 1996. In the present study, the 2E8 Fv gene was inserted into a baculovirus shuttle vector and novel protein was expressed in an IgG1 form in the Sf9 insect cell line. VH2E8 and VL2E8 genes were cloned and inserted into the baculovirus shuttle vector pAc‑κ‑CH3 to form pAc‑κ‑CH3‑VH2E8‑VL2E8. Sf9 cells were then transfected with the reconstructed baculovirus shuttle vector. Novel protein expressed by the Sf9 cells was identified by immunofluorescence and western blot analysis, while activity levels were analyzed by flow cytometry (FCM). Sequencing demonstrated that the VH2E8 and VL2E8 fragments were inserted into pAc‑κ‑CH3 correctly. The immunofluorescence, western blot analysis and FCM results indicated that active recombinant antibody was expressed in the cytoplasm of Sf9 cells, but not in the culture supernatant. Thus, functional recombinant antibody was expressed successfully in the cytoplasm of Sf9 cells, but was not secreted into the culture supernatant. Therefore, the present study demonstrates that it is possible to modify mouse IgM to mouse‑human chimeric IgG1 while retaining reasonable biological activity.

View Figures

View References

1	Salzer WL, Devidas M, Carroll WL, Winick N, Pullen J, Hunger SP and Camitta BA: Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984–2001: a report from the children’s oncology group. Leukemia. 24:355–370. 2010.
2	Portell CA and Advani AS: Antibody therapy for acute lymphoblastic leukemia. Curr Hematol Malig Rep. 7:153–159. 2012. View Article : Google Scholar : PubMed/NCBI
3	Shimoni A, Zwas ST, Oksman Y, Hardan I, Shem-Tov N, Rand A, Yerushalmi R, Avigdor A, Ben-Bassat I and Nagler A: Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin’s lymphoma. Bone Marrow Transplant. 41:355–361. 2008.PubMed/NCBI
4	Pagel JM, Appelbaum FR, Eary JF, Rajendran J, Fisher DR, Gooley T, Ruffner K, Nemecek E, Sickle E, Durack L, Carreras J, Horowitz MM, Press OW, Gopal AK, Martin PJ, Bernstein ID and Matthews DC: ¹³¹I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood. 107:2184–2191. 2006. View Article : Google Scholar
5	Herrera L, Stanciu-Herrera C, Morgan C, Ghetie V and Vitetta ES: Anti-CD19 immunotoxin enhances the activity of chemotherapy in severe combined immunodeficient mice with human pre-B acute lymphoblastic leukemia. Leuk Lymphoma. 47:2380–2387. 2006. View Article : Google Scholar : PubMed/NCBI
6	Feldman EJ, Brandwein J, Stone R, Kalaycio M, Moore J, O’Connor J, Wedel N, Roboz GJ, Miller C, Chopra R, Jurcic JC, Brown R, Ehmann WC, Schulman P, Frankel SR, De Angelo D and Scheinberg D: Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Oncol. 23:4110–4116. 2005. View Article : Google Scholar
7	Dungarwalla M, Evans SO, Riley U, Catovsky D, Dearden CE and Matutes E: High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy. Haematologica. 93:475–476. 2008. View Article : Google Scholar : PubMed/NCBI
8	Chen YH, Tang YM, Shen GQ, Song H, Yang SL, Shi SW, Qian BQ, Xu WQ and Ning BT: The comparison of expression patterns of CD19 and CD20 on 321 cases of acute leukemia. Zhejiang Medical Journal. 25:461–463. 2003.(In Chinese).
9	Jefferis R: Aglycosylated antibodies and the methods of making and using them: WO2008030564. Expert Opin Ther Pat. 19:101–105. 2009. View Article : Google Scholar : PubMed/NCBI
10	Tsai LK, Pop LM, Liu X and Vitetta ES: A comparison of the anti-tumor effects of a chimeric versus murine anti-CD19 immunotoxins on human B cell lymphoma and Pre-B acute lymphoblastic leukemia cell lines. Toxins (Basel). 3:409–419. 2011. View Article : Google Scholar : PubMed/NCBI
11	Davies JK, Singh H, Huls H, Yuk D, Lee DA, Kebriaei P, Champlin RE, Nadler LM, Guinan EC and Cooper LJ: Combining CD19 redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies. Cancer Res. 70:3915–3924. 2010. View Article : Google Scholar : PubMed/NCBI
12	Michálek J, Collins RH and Vitetta ES: Clinical-scale selective depletion of alloreactive T cells using an anti-CD25 immunotoxin. Neoplasma. 50:296–299. 2003.PubMed/NCBI
13	Goto S, Goto H, Tanoshima R, Kato H, Takahashi H, Sekiguchi O and Kai S: Serum sickness with an elevated level of human anti-chimeric antibody following treatment with rituximab in a child with chronic immune thrombocytopenic purpura. Int J Hematol. 89:305–309. 2009. View Article : Google Scholar : PubMed/NCBI
14	Liang M, Dubel S, Li D, Queitsch I, Li W and Bautz EK: Baculovirus expression cassette vectors for rapid production of complete human IgG from phage display selected antibody fragments. J Immunol Methods. 247:119–130. 2001. View Article : Google Scholar
15	van der Geld YM, Oost-Kort W, Limburg PC, Specks U and Kallenberg CG: Recombinant proteinase 3 produced in different expression systems: recognition by anti-PR3 antibodies. J Immunol Methods. 244:117–131. 2000.PubMed/NCBI
16	Filpula D: Antibody engineering and modification technologies. Biomol Eng. 24:201–215. 2007. View Article : Google Scholar : PubMed/NCBI
17	Wang Y, Feng J, Huang Y, Gu X, Sun Y, Li Y and Shen B: The design, construction and function of a new chimeric anti-CD20 antibody. J Biotechnol. 129:726–731. 2007. View Article : Google Scholar : PubMed/NCBI
18	Tang Y and Guo S: Preparation, identification and preliminary application of B lineage specific monoclonal antibody ZCH-4-2E8. Journal of Zhejiang University Science ABC. 23:246–249. 1994.